This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

I'm especially optimistic about the prospects for Vertex's new pain drug Journavx. Its U.S. Food and Drug Administration (FDA) approval in January 2025 marked the first U.S. approval of a non ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...